Catalysts
- AL001: a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.
- ALZN002: an active immunotherapy vaccine for Alzheimer's. Phase I/IIA studies will be resumed Q1/2 2026 after new research partnerships.
The rising prevalence of neurodegenerative diseases and the lack of effective treatments present a large market opportunity. Sector momentum in biotech, especially for novel approaches in CNS diseases, adds further tailwinds. However, regulatory hurdles and competition are ongoing risks
Assumptions
- If at least one of the pipeline products receives FDA approval and is commercialized, revenues could rise significantly by 2030 due to the large addressable market for neuropsychiatric and mood disorders, where few effective options exist today.
- Currently loss-making, Alzamend could achieve positive margins by 2028-2030 if it secures commercial approval and launches AL001 or ALZN002. If clinical trials fail, however, losses will likely continue.
Risks
- high risk of clinical failure, potential for negative side effects, regulatory setbacks, or issues with manufacturing/funding remain.
- FDA/EMA rejections, or approval of new competitor drugs with superior data or pricing, would materially impact future prospects.
- competitors list: Generation Bio (GBIO), OnKure Therapeutics (OKUR), Rein Therapeutics (RNTX), Dyadic International (DYAI), Biodexa Pharmaceuticals (BDRX), MIRA Pharmaceuticals (MIRA), NanoViricides (NNVC), Tenax Therapeutics (TENX), JATT Acquisition (JATT)
Valuation
- In the next 3-5 years the company will likely remain focused on clinical development, seeking partnerships and funding. If successful, in 10 years it could become a key player in CNS therapies; if not, it may exit the market.
- Given that Alzamend Neuro currently trades at $2.42, the company’s valuation reflects a cautious market outlook regarding its ability to achieve successful R&D and clinical milestones over the next few years. Recent forecasts project a 2030 target price with a median around $2.90, potential highs up to $5.42, but also the real risk of dropping below $1 in the absence of meaningful clinical progress or positive news flow.This means that potential upside is limited unless significant clinical breakthroughs or product approvals are achieved—particularly for AL001 or ALZN002 by 2028–2030. In such a scenario, valuation multiples (P/S, P/E) could rise above the biotech sector averages (currently, U.S. biotech/pharma P/E is ~20-21x, and P/S is ~3-6x). However, until then, the company remains in a pre-profit phase, with inherent regulatory and clinical risks justifying lower multiples and considerable volatility
How well do narratives help inform your perspective?
Disclaimer
The user jacopo22295 has a position in NasdaqCM:ALZN. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.